Sign Up to like & get
recommendations!
1
Published in 2018 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.aar7535
Abstract: Myc-driven cancers can be targeted with the IRE1α inhibitor. Myc-driven cancers can be targeted with the IRE1α inhibitor.
read more here.
Keywords:
medicine;
driven cancer;
stressing myc;
myc driven ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0276579
Abstract: Metabolic reprogramming is now considered a hallmark of cancer cells. KRas-driven cancer cells use glutaminolysis to generate the tricarboxylic acid cycle intermediate α-ketoglutarate via a transamination reaction between glutamate and oxaloacetate. We reported previously that…
read more here.
Keywords:
cancer cells;
atp citrate;
citrate lyase;
driven cancer ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Cancers"
DOI: 10.3390/cancers14153818
Abstract: Simple Summary The discovery of microRNAs has revolutionized the world of science and opened up new opportunities in cancer treatment. miRNA dysregulation plays a crucial role in carcinogenesis processes, such as invasion, metastasis, and angiogenesis,…
read more here.
Keywords:
microrna driven;
driven cancer;
miracle microrna;
tumor ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2017 at "Theranostics"
DOI: 10.7150/thno.20460
Abstract: Cancer is a very complex disease, where cell alterations (i.e. gene mutations, dysregulated signaling pathway(s) and epigenetic modifications) contribute to its development and progression. Elucidating the connections among these cell modifications is a critical challenge,…
read more here.
Keywords:
cancer;
v600e driven;
driven cancer;
raf v600e ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Theranostics"
DOI: 10.7150/thno.67300
Abstract: Cancer immunotherapy has made tremendous clinical progress in advanced-stage malignancies. However, patients with various tumors exhibit a low response rate to immunotherapy because of a powerful immunosuppressive tumor microenvironment (TME) and insufficient immunogenicity of tumors.…
read more here.
Keywords:
driven cancer;
immunotherapy;
pdt driven;
cancer immunotherapy ... See more keywords